Is NCT01862081 results overdue?

Yes — results are overdue. Primary completion was 2017-06-09; the FDAAA-801 reporting deadline (2018-06-09) passed 2934 days ago and no results are posted on ClinicalTrials.gov.

A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

NCT ID	NCT01862081 ↗
Sponsor	Genentech, Inc. (INDUSTRY)
Phase	PHASE1
Status	COMPLETED
Primary completion	2017-06-09 (ACTUAL)
Reporting deadline	2018-06-09 (completion + 365d)
Days overdue	2934
Results posted	No — check results tab ↗
FDA-regulated	drug: yes, device: no
Provenance	Flagged overdue on 2026-06-21 · SHA-256 `743bcd53ae588d94…` (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT01862081. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.